Brentuximab vedotin therapy for cutaneous lesions in T-prolymphocytic leukemia: a case report

被引：0
|
作者：
Senchak, Jordan [1 ]
Pickens, Peter [2 ]
机构：
[1] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA
[2] Abington Mem Hosp, Dept Hematol Oncol, Abington, PA 19001 USA
来源：
HEMATOLOGY REPORTS | 2016年 / 8卷 / 03期
关键词：
T-prolymphocytic leukemia; brentuximab vedotin; alemtuzumab;
D O I：
10.4081/hr.2016.6593
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We present an 88-year-old male with simultaneous T-cell prolymphocytic leukemia and stable smoldering myeloma with excellent initial response to three months of alemtuzumab. The patient relapsed at twelve months with severe cutaneous disease. Biopsy of a representative plaque demonstrated CD30 positivity in rare malignant lymphocytes. The patient demonstrated no response to reintroduction with a full course of alemtuzumab. He was therefore treated with brentuximab vedotin, resulting in partial remission of skin involvement that persisted for three months.
引用
收藏
页码：42 / +
页数：2
相关论文
共 50 条
  • [31] Cutaneous T-Cell Lymphomas - under targeted Therapy with Brentuximab Vedotin and Mogamulizumab
    Bartels, P.
    Debus, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 51 - 51
  • [32] Brentuximab vedotin/nivolumabMaculopapular rash: case report
    Reactions Weekly, 2019, 1738 (1) : 63 - 63
  • [33] Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience
    Damlaj, Moussab
    Sulai, Nanna H.
    Oliveira, Jennifer L.
    Ketterling, Rhett P.
    Hashmi, Shahrukh
    Witzig, Thomas
    Nowakowski, Grzegorz
    Call, Timothy G.
    Shanafelt, Tait D.
    Ding, Wei
    Hogan, William J.
    Litzow, Mark R.
    Patnaik, Mrinal M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11): : 699 - 704
  • [34] T-Cell Prolymphocytic Leukemia: A Case Report
    Jimenez, Fernando
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S354 - S354
  • [35] Brentuximab vedotin/crizotinibDevelopment of resistance: case report
    Reactions Weekly, 2016, 1600 (1) : 59 - 59
  • [36] Chemoimmunotherapy with bendamustine hydrochloride and alemtuzumab demonstrates synergism in T-prolymphocytic leukemia
    Yong, Hao Xiang
    Linn, Yeh Ching
    Ong, Kiat Hoe
    Tan, Daryl
    LEUKEMIA RESEARCH, 2012, 36 (08) : E163 - E165
  • [37] Seropositive polyarthritis and skin manifestations in T-prolymphocytic leukemia/sezary cell leukemia variant
    Dybjer, A
    Hellquist, L
    Johansson, B
    Rydgren, L
    Billström, R
    LEUKEMIA & LYMPHOMA, 2000, 37 (3-4) : 437 - +
  • [38] Brentuximab vedotin/IGF methotrexateSarcoidosis: case report
    Reactions Weekly, 2017, 1673 (1) : 103 - 103
  • [39] CAMPATH-1H in the treatment of T-prolymphocytic leukemia (T-PLL).
    Cazin, B
    Wetterwald, M
    Ojeda, M
    Mahé, B
    Bauters, F
    BLOOD, 1999, 94 (10) : 125A - 125A
  • [40] Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and T-Prolymphocytic Leukemia Presenting with Lymphocytosis, Skin Lesions, and Generalized Lymphadenopathy
    Sakhdari, Ali
    Tang, Guilin
    Ginsberg, Lawrence E.
    Hirsch-Ginsberg, Cheryl F.
    Bueso-Ramos, Carlos E.
    Medeiros, L. Jeffrey
    Miranda, Roberto N.
    CASE REPORTS IN PATHOLOGY, 2019, 2019
12345